Library

CASE STUDY

Learn how a 2020 fierce 15 pharma, greatly reduced costs by 50% and site burden by 75% in phase II PEGASUS Alzheimer’s trial.

Download our clinical trial case study now!

GET THE CASE STUDY

PUBLICATION

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Steve Simpson-Yap, ... Nikola Lazovski, ... Liesbet Peeters. 2021. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology, October.

LEARN MORE

WHITEPAPER

Data Security and Quality Framework

LEARN MORE

CASE STUDY

Phase II PEGASUS Alzheimer’s trial.

LEARN MORE

Have a look at the latest publications, whitepapers, case studies and many more.

Support your Alzheimer's Phase II trial by incorporating neuroimaging processing tools

Learn how a 2020 fierce 15 pharma, greatly reduced costs by 50% and site burden by 75% in phase II PEGASUS Alzheimer’s trial.

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Data Security and Quality Framework

Phase II PEGASUS Alzheimer’s trial.

Streamlining Medical Imaging to Support Alzheimer’s Disease Phase II Trial

Data Security and Quality Framework at QMENTA

QMENTA's Central Reading Workflow, CRC on Your Data Management System - Short Demo

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Interview: Professor Adam Waldman, The University of Edinburgh

Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS) Study Protocol for a Prospective Multi-center Trial

Co-development of Digital RANO Tumor Segmentation Tool and Execution of the Brain Matrix Consortium Study with the University of Edinburgh

On the generalizability of diffusion MRI signal representations across acquisition parameters, sequences and tissue types: chronicles of the MEMENTO challenge

Learn more about our clients success

Looking for more scientific publications?

Here are more technical topics

One tool for all your imaging studies